- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Serum Institute seeks CDSCO permission for Phase-3 trial of Covovax as booster dose in children aged 2-18
The study will evaluate the immunogenicity and safety of the vaccine as a booster dose in comparison with the placebo.
New Delhi: The Serum Institute of India (SII) has sought permission from the country's drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday.
The Drugs Controller General of India (DCGI) had granted permission in March for conducting Phase-3 clinical trial of Covovax as a booster dose in adults.
In an application, SII Director for Government and Regulatory Affairs Prakash Kumar Singh has sought permission to conduct the Phase-3, observer-blinded, randomised, controlled study in children aged two to 18 years in India who have already received primary vaccination against COVID-19 with Covovax at least six months ago.
The study will evaluate the immunogenicity and safety of the vaccine as a booster dose in comparison with the placebo.
Singh is learnt to have stated that it has become evident that the protection offered against COVID-19 wanes after a two-dose schedule of vaccines and that more than 100 countries have started administering booster doses.
A total of 408 eligible children of two to 18 years of age who have completed the primary two-dose schedule of Covovax at least six months ago will be enrolled in the study.
The Hyderabad-based Bharat Biotech has recently sought permission from India's drug regulator to conduct Phase-2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years.
Read also: Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial for 2-18 age group
Covovax was approved for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group, subject to certain conditions, on March 9.
India began administering precaution doses of the vaccines to the healthcare and frontline workers and those aged 60 and above with comorbidities from January 10 this year.
The comorbidity clause for people aged above 60 was subsequently removed.
India began administering precaution doses of COVID-19 vaccines to all aged above 18 years at private vaccination centres from April 10.
Currently all those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751